Status:
UNKNOWN
Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas
Lead Sponsor:
Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions:
Infantile Hemangioma
Eligibility:
All Genders
Up to 12 years
Phase:
PHASE3
Brief Summary
Through this study, the investigators shall compare the effectiveness of atenolol with propranolol in the treatment of IH. In addition, the investigators shall try to elucidate the mechanism of action...
Detailed Description
AIMS AND OBJECTIVES: 1. To compare the effectiveness and safety of oral atenolol versus oral propranolol in the treatment of infantile hemangiomas. 2. To elucidate the mechanism of action of atenolol...
Eligibility Criteria
Inclusion
- Children diagnosed with problematic infantile hemangiomas
- Potentially disfiguring infantile hemangiomas at any site.
- Functionally threatening infantile hemangiomas near the eyes, nose, natural orifices, limbs, genitalia.
- Ulcerated infantile hemangiomas.
- Segmental infantile hemangiomas.
- Uncomplicated progressive infantile hemangiomas with unpredictable future course.
- Age group: less than 1 year of age.
- Either sex
- Multiple hemangiomas
Exclusion
- Infants with heart disease, cardiac arrhythmias
- Broncho -obstructive disease.
- Premature infants with corrected age less than 40 weeks.
- Known hypoglycemia
- Diabetes mellitus
- Hypertension
- Hypotension
- Liver failure
- Visceral hemangiomas
- PHACES syndrome
Key Trial Info
Start Date :
March 24 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03237637
Start Date
March 24 2017
End Date
December 1 2018
Last Update
August 28 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PGIMER
Chandigarh, India, 160012